ISRG stock: Pre-market $490.16 on 09 Mar 2026 shows AI-driven growth potential

We see ISRG stock trading pre-market at $490.16 on 09 Mar 2026 as investors weigh AI-driven product expansion and a rich valuation. Intuitive Surgical, Inc. (ISRG) on the NASDAQ faces a near-term test from upcoming earnings on 21 Apr 2026 and recent FDA and European moves that could lift procedure volumes. Our quick view ties robotics, software subscriptions, and diagnostics to revenue drivers while noting a high PE of 62.36 and market cap of $174.07 billion USD.

ISRG stock: pre-market price and market snapshot

ISRG stock opened pre-market at $490.16 on NASDAQ in the United States with volume 2,087,221.00 and average volume 1,907,860.00. The share price sits below the 50-day average of $526.33 and the 200-day average of $513.18, and the stock traded between $478.20 and $491.07 yesterday.

ISRG stock: recent catalysts and AI strategy

Intuitive Surgical, Inc. has recent positive catalysts including expanded da Vinci 5 cardiac indications and direct distribution in Southern Europe, which can raise system sales and service revenue. The company is pushing software and digital offerings, including a potential paid My Intuitive+ subscription and AI-enabled analytics tied to its platforms and the Ion endoluminal system, which positions ISRG stock in the AI stocks conversation.

ISRG stock: fundamentals and valuation

Intuitive Surgical reports EPS 7.86 and PE 62.36, and the business shows strong margins with a net margin near 28.38% and ROE around 16.39%. Key ratios show ample cash on the balance sheet with cash per share $16.72 and low leverage (debt to equity 0.02), but price-to-sales of ~17.3 and price-to-free-cash-flow near 69.93 flag a high multiple to justify with continued growth.

ISRG stock: technicals and short-term trading outlook

Technicals show the stock with RSI 40.63 and ADX 29.53 indicating a defined trend and room for recovery. The 50-day moving average slope is flattening and Bollinger middle band sits at $495.94, giving resistance near $509.69 and support around $482.19, which traders will watch into earnings and any AI product updates.

ISRG stock: analyst views, targets and risks

Wall Street targets vary from $550.00 (Evercore) to $750.00 (Sanford C. Bernstein) with an average near $615.86, showing a wide range tied to execution and valuation comfort. Major risks include high valuation sensitivity, recent insider selling, and adoption pace for new cardiac indications and software monetization. Positives include recurring consumables sales, services revenue, and expanding diagnostics exposure.

Meyka AI grade and forecast for ISRG stock

Meyka AI rates ISRG with a score out of 100: 79.73 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of $585.45, implying an upside of 19.44% versus the current $490.16, while the quarterly model sits at $485.77, effectively flat to slightly negative in the near term. Forecasts are model-based projections and not guarantees.

Final Thoughts

ISRG stock trades at $490.16 pre-market on 09 Mar 2026 as investors balance a strong growth story against a premium valuation. Intuitive Surgical’s strengths include durable margins, cash generation, a leading install base for da Vinci systems, and a credible path to subscription and diagnostics revenue via My Intuitive+ and the Ion platform. Key catalysts ahead are the 21 Apr 2026 earnings and execution on cardiac indications and European expansion. Analyst targets range widely from $550.00 to $750.00, and Meyka AI’s model forecasts $585.45 for the year, implying ~19.44% upside from today’s price; forecasts are model-based projections and not guarantees. We use this as a focused view for AI stocks investors considering exposure to robotic surgery, and we note valuation sensitivity and insider flows as close-term risk factors. For real-time monitoring we recommend combining earnings updates, procedural adoption data, and software subscription rollouts in your checklist, and consulting Meyka AI as an AI-powered market analysis platform for live signals.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.